Autor: |
Zhang XP; Oncology and Immunology Research Section, Lederle Laboratories, Division of American Cyanamid, Pearl River, NY 10965., Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Annable T, Arceci RJ, Durr FE, Greenberger LM |
Jazyk: |
angličtina |
Zdroj: |
Oncology research [Oncol Res] 1994; Vol. 6 (7), pp. 291-301. |
Abstrakt: |
Bisantrene, mitoxantrone, and anthracyclines are anthracene derivatives that interact with DNA and are used for the treatment of cancers. The mechanisms of resistance to bisantrene are unknown. Here we show that cells that overexpress low levels of P-glycoprotein or are transfected with human MDR1 have approximately 10-fold greater resistance to bisantrene compared to vinblastine, doxorubicin, or colchicine. Furthermore, bisantrene can be used to select for high-level P-glycoprotein-mediated multiple drug resistance in a human colon carcinoma cell line, LS 174T, and the drug blocks photoaffinity labeling of P-glycoprotein. The data suggest that bisantrene is an excellent substrate for P-glycoprotein. These findings could influence subsequent clinical evaluation of bisantrene for the treatment of cancer. |
Databáze: |
MEDLINE |
Externí odkaz: |
|